It is okay to report the revenue but if we are being true stewards to patients, communities, and national health we also need to hold the tension of what might be festering below the surface.
When I tease out metrics of innovation I tend to go more granular than stakeholders prefer. That's okay with me. I no longer accept projects where clients have a clear objective and request data sourcing that supports their premise. Why not formulate the data question and see what data best contributes to the facts?
Listen to Vinay Prasad, MD, MPH and hopefully you will become more critical of eminence based medicine and more familiar with evidence based medicine.
This particular podcast (link below) where he takes you step by step through a careful review of BEACON clinical trial is riveting. His reasons for being skeptical about the role of medical writers is exactly why I no longer write on assignment. Well, hold on. I would write on assignment if it was less secretarial (write this but not that) and was strictly focused on a 360 perspective of available data--but...
Vinay also wrote this editorial in theBMJ, BEACON trial in colorectal cancer is “single worst reported,” says critic
You can understand his point when you listen to the podcast either before or after you may have seen the press from ASCO Post Staff:
A survey that circulates every year about need assessment writing in continuing medical education continually demonstrates to me that we need these skills. Not the ability to code in Python but the ability to perhaps write a single line of code that can analyze a dataset or generate a visualization.
If you are curious about the cost of innovation, here is an easy dashboard you can begin using right now--no data manipulation required.
I recommend that you familiarize yourself with the FDA Adverse Events Reporting System (FAERS) Public Dashboard.